China
Africa
Explore chapters and articles related to this topic
H
Published in Caroline Ashley, Aileen Dunleavy, John Cunningham, The Renal Drug Handbook, 2018
Caroline Ashley, Aileen Dunleavy, John Cunningham
The main metabolic pathway is the hydrolytic cleavage of the ester bond. Orally administered hyoscine butylbromide is excreted in the faeces and in the urine. Studies in man show that 2–5% of radioactive doses is eliminated renally after oral, and 0.7–1.6% after rectal administration. Approximately 90% of recovered radioactivity can be found in the faeces after oral administration. The urinary excretion of hyoscine butylbromide is less than 0.1% of the dose. The metabolites excreted via the renal route bind poorly to muscarinic receptors and are therefore not considered to contribute to the effect of the hyoscine butylbromide.
Information on level of drugs into breastmilk
Published in Wendy Jones, Breastfeeding and Medication, 2018
Hyoscine butylbromide is used to relieve spasms of the gut and colic. It has anti-muscarinic activity so may produce constipation, blurred vision, urinary retention as well as a dry mouth in the mother. It is poorly absorbed from the gut. No levels in breastmilk have been reported from studies. It is licenced at half the adult dose for children over 6 years (10 mg three times daily). Alternative preparations are available so it should be a third-line choice unless merbeverine and peppermint oil are ineffective.
Managing the adverse effects of analgesics
Published in Mervyn Dean, Juan-Diego Harris, Claud Regnard, Jo Hockley, Symptom Relief in Palliative Care, 2018
Mervyn Dean, Juan-Diego Harris, Claud Regnard, Jo Hockley
Antispasmodics: Hyoscine butylbromide (Buscopan) (Canada only) usually has few adverse effects, but hyoscine hydrobromide (known as scopolamine in the US) can cause marked central anti-muscarinic effects. In the US use hyoscyamine (Levsin) 0.125–0.25 mg PO/SL tid-qid PRN.
Clinical and Nutritional Care Pathways of Patients with Malignant Bowel Obstruction: A Retrospective Analysis in a Tertiary UK Center
Published in Nutrition and Cancer, 2021
Pinal S Patel, Konstantinos C. Fragkos, Niamh Keane, Katrine Cauldwell, Francis O’Hanlon, Jennifer Rogers, Sarah Obbard, John Barragry, Gregory Sebepos-Rogers, Jane Neerkin, Shameer Mehta, Farooq Rahman, Simon Di Caro
High dose dexamethasone was prescribed in 40.2% patients with 8 mg median dose (range 8–16mg). 66.7% patients were prescribed one or more parenteral opioids. The most common opioids prescribed were morphine sulfate (46.2%) and oxycodone (24.8%). 92.3% patients were prescribed parenteral anti-emetics. Of these 64.8% used combination therapy. The most frequently prescribed anti-emetics were cyclizine (59.8%) and ondansetron (53.9%). Laxatives were used in 67.5% patients, most commonly movicol (30.8%) and sodium docusate (27.4%). Injectable anti-secretories were used in 28 (23.9%) patients. The types of parenteral anti-secretories prescribed were hyoscine butylbromide, octreotide, or a combination of both.